CA2937088C - Method for generating high-titer hepatitis e virus stocks and titration assay for hepatitis e virus - Google Patents
Method for generating high-titer hepatitis e virus stocks and titration assay for hepatitis e virus Download PDFInfo
- Publication number
- CA2937088C CA2937088C CA2937088A CA2937088A CA2937088C CA 2937088 C CA2937088 C CA 2937088C CA 2937088 A CA2937088 A CA 2937088A CA 2937088 A CA2937088 A CA 2937088A CA 2937088 C CA2937088 C CA 2937088C
- Authority
- CA
- Canada
- Prior art keywords
- hev
- virus
- concentration
- reaction mixture
- titer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000724675 Hepatitis E virus Species 0.000 title claims abstract description 189
- 238000000034 method Methods 0.000 title claims abstract description 97
- 238000003556 assay Methods 0.000 title claims abstract description 32
- 238000004448 titration Methods 0.000 title claims abstract description 20
- 229920000209 Hexadimethrine bromide Polymers 0.000 claims abstract description 49
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 49
- 239000000523 sample Substances 0.000 claims description 39
- 239000001963 growth medium Substances 0.000 claims description 33
- 239000011541 reaction mixture Substances 0.000 claims description 33
- 108091033319 polynucleotide Proteins 0.000 claims description 23
- 102000040430 polynucleotide Human genes 0.000 claims description 23
- 239000002157 polynucleotide Substances 0.000 claims description 23
- 239000002299 complementary DNA Substances 0.000 claims description 20
- 239000002609 medium Substances 0.000 claims description 18
- 238000000338 in vitro Methods 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 12
- 108091034117 Oligonucleotide Proteins 0.000 claims description 11
- 238000012258 culturing Methods 0.000 claims description 11
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 230000000295 complement effect Effects 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 238000011529 RT qPCR Methods 0.000 claims description 5
- 230000003321 amplification Effects 0.000 claims description 5
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 5
- 230000000644 propagated effect Effects 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 238000011002 quantification Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 claims description 2
- 239000006143 cell culture medium Substances 0.000 abstract description 14
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 126
- 241000700605 Viruses Species 0.000 description 43
- 238000004113 cell culture Methods 0.000 description 23
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 17
- 239000012091 fetal bovine serum Substances 0.000 description 17
- 208000015181 infectious disease Diseases 0.000 description 16
- 238000002944 PCR assay Methods 0.000 description 10
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 238000007747 plating Methods 0.000 description 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000007995 HEPES buffer Substances 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- 241000282898 Sus scrofa Species 0.000 description 3
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229960002518 gentamicin Drugs 0.000 description 3
- 238000012606 in vitro cell culture Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 244000309715 mini pig Species 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229920006317 cationic polymer Polymers 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 210000005265 lung cell Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- KZKAYEGOIJEWQB-UHFFFAOYSA-N 1,3-dibromopropane;n,n,n',n'-tetramethylhexane-1,6-diamine Chemical compound BrCCCBr.CN(C)CCCCCCN(C)C KZKAYEGOIJEWQB-UHFFFAOYSA-N 0.000 description 1
- OGHAROSJZRTIOK-FCIPNVEPSA-O 7-methylguanosine Chemical compound C1=2N=C(N)NC(=O)C=2[N+](C)=CN1[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O OGHAROSJZRTIOK-FCIPNVEPSA-O 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241001122120 Hepeviridae Species 0.000 description 1
- 241001112094 Hepevirus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000011021 bench scale process Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 1
- 210000004407 endothelial cell of postcapillary venule of lymph node Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 201000010284 hepatitis E Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 229950007870 hexadimethrine bromide Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000007859 qualitative PCR Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000012340 reverse transcriptase PCR Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/067—Hepatocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
- C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/05—Adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/28011—Hepeviridae
- C12N2770/28111—Hepevirus, e.g. hepatitis E virus
- C12N2770/28121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/28011—Hepeviridae
- C12N2770/28111—Hepevirus, e.g. hepatitis E virus
- C12N2770/28151—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562195936P | 2015-07-23 | 2015-07-23 | |
| US62/195.936 | 2015-07-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2937088A1 CA2937088A1 (en) | 2017-01-23 |
| CA2937088C true CA2937088C (en) | 2022-06-21 |
Family
ID=56409494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2937088A Active CA2937088C (en) | 2015-07-23 | 2016-07-22 | Method for generating high-titer hepatitis e virus stocks and titration assay for hepatitis e virus |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US10208291B2 (enExample) |
| EP (1) | EP3121267B1 (enExample) |
| JP (1) | JP6588397B2 (enExample) |
| KR (1) | KR102154380B1 (enExample) |
| CN (1) | CN106367397B (enExample) |
| AR (1) | AR106015A1 (enExample) |
| AU (1) | AU2016204734B2 (enExample) |
| BR (1) | BR102016016677A2 (enExample) |
| CA (1) | CA2937088C (enExample) |
| CL (1) | CL2016001768A1 (enExample) |
| ES (1) | ES2669021T3 (enExample) |
| HU (1) | HUE036699T2 (enExample) |
| IL (1) | IL246634B (enExample) |
| MX (1) | MX375106B (enExample) |
| MY (1) | MY176204A (enExample) |
| NZ (1) | NZ722213A (enExample) |
| PL (1) | PL3121267T3 (enExample) |
| PT (1) | PT3121267T (enExample) |
| RU (1) | RU2691123C1 (enExample) |
| SG (1) | SG10201605867UA (enExample) |
| TW (1) | TWI666322B (enExample) |
| UY (1) | UY36778A (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102158641B1 (ko) * | 2019-03-06 | 2020-09-22 | 대한민국 | 야누스 인산화효소 저해제 및 헥사디메트린 브로마이드를 포함하는 바이러스 배양용 조성물 및 이를 이용한 바이러스 배양 방법 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6506604B2 (en) * | 1993-06-11 | 2003-01-14 | Cell Genesys, Inc. | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells |
| US6217858B1 (en) * | 1997-02-11 | 2001-04-17 | Hadasit & Medical Research Services & Development Company, Ltd. | Pharmaceutical composition for treating hepatitis B virus (HBV) infection |
| WO2003001198A1 (en) * | 2001-06-21 | 2003-01-03 | Regents Of The University Of California | Immortalization of human cells by the ectopic expression of human telomerase reverse transcriptase |
| WO2007046962A2 (en) * | 2005-09-02 | 2007-04-26 | The University Of Maryland, Baltimore | Cell lines harboring hepatitis virus and methods for using thereof |
| JP2012504647A (ja) * | 2008-10-03 | 2012-02-23 | ザ ロックフェラー ユニヴァーシティ | 新規なｈｃｖ侵入因子、オクルディン |
| US9181530B2 (en) * | 2011-01-10 | 2015-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Infectious hepatitis E virus genotype 3 recombinants |
| US9789139B2 (en) * | 2011-06-10 | 2017-10-17 | Bluebird Bio, Inc. | Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy |
-
2016
- 2016-07-06 IL IL246634A patent/IL246634B/en active IP Right Grant
- 2016-07-07 UY UY0001036778A patent/UY36778A/es not_active Application Discontinuation
- 2016-07-08 AU AU2016204734A patent/AU2016204734B2/en active Active
- 2016-07-08 MX MX2016009048A patent/MX375106B/es active IP Right Grant
- 2016-07-08 RU RU2016127546A patent/RU2691123C1/ru active
- 2016-07-11 EP EP16178844.3A patent/EP3121267B1/en active Active
- 2016-07-11 HU HUE16178844A patent/HUE036699T2/hu unknown
- 2016-07-11 PL PL16178844T patent/PL3121267T3/pl unknown
- 2016-07-11 CL CL2016001768A patent/CL2016001768A1/es unknown
- 2016-07-11 PT PT161788443T patent/PT3121267T/pt unknown
- 2016-07-11 ES ES16178844.3T patent/ES2669021T3/es active Active
- 2016-07-12 MY MYPI2016702506A patent/MY176204A/en unknown
- 2016-07-15 NZ NZ722213A patent/NZ722213A/en not_active IP Right Cessation
- 2016-07-18 CN CN201610566601.8A patent/CN106367397B/zh active Active
- 2016-07-18 SG SG10201605867UA patent/SG10201605867UA/en unknown
- 2016-07-19 US US15/213,766 patent/US10208291B2/en active Active
- 2016-07-19 BR BR102016016677-2A patent/BR102016016677A2/pt not_active Application Discontinuation
- 2016-07-20 TW TW105122892A patent/TWI666322B/zh not_active IP Right Cessation
- 2016-07-21 AR ARP160102202A patent/AR106015A1/es not_active Application Discontinuation
- 2016-07-22 JP JP2016144065A patent/JP6588397B2/ja active Active
- 2016-07-22 CA CA2937088A patent/CA2937088C/en active Active
- 2016-07-22 KR KR1020160093629A patent/KR102154380B1/ko not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AR106015A1 (es) | 2017-12-06 |
| CN106367397B (zh) | 2021-07-20 |
| HUE036699T2 (hu) | 2018-07-30 |
| EP3121267A1 (en) | 2017-01-25 |
| RU2691123C1 (ru) | 2019-06-11 |
| AU2016204734A1 (en) | 2017-02-09 |
| EP3121267B1 (en) | 2018-03-28 |
| KR20170012140A (ko) | 2017-02-02 |
| ES2669021T3 (es) | 2018-05-23 |
| JP2017023143A (ja) | 2017-02-02 |
| CN106367397A (zh) | 2017-02-01 |
| KR102154380B1 (ko) | 2020-09-10 |
| PL3121267T3 (pl) | 2018-07-31 |
| CL2016001768A1 (es) | 2017-05-12 |
| IL246634B (en) | 2020-08-31 |
| MX375106B (es) | 2025-03-06 |
| BR102016016677A2 (pt) | 2019-02-12 |
| TWI666322B (zh) | 2019-07-21 |
| IL246634A0 (en) | 2016-12-29 |
| UY36778A (es) | 2016-09-30 |
| MX2016009048A (es) | 2017-01-23 |
| AU2016204734B2 (en) | 2019-11-21 |
| SG10201605867UA (en) | 2017-02-27 |
| CA2937088A1 (en) | 2017-01-23 |
| NZ722213A (en) | 2019-04-26 |
| US10208291B2 (en) | 2019-02-19 |
| JP6588397B2 (ja) | 2019-10-09 |
| US20170022481A1 (en) | 2017-01-26 |
| PT3121267T (pt) | 2018-04-26 |
| MY176204A (en) | 2020-07-24 |
| TW201704468A (zh) | 2017-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lau et al. | Nucleic acid sequence-based amplification methods to detect avian influenza virus | |
| Guillaume et al. | Specific detection of Nipah virus using real-time RT-PCR (TaqMan) | |
| Lau et al. | Isolation and characterization of a novel Betacoronavirus subgroup A coronavirus, rabbit coronavirus HKU14, from domestic rabbits | |
| Gillim-Ross et al. | Discovery of novel human and animal cells infected by the severe acute respiratory syndrome coronavirus by replication-specific multiplex reverse transcription-PCR | |
| Rogee et al. | New models of hepatitis E virus replication in human and porcine hepatocyte cell lines | |
| Ambrose et al. | Virus discovery by sequence‐independent genome amplification | |
| Sridhar et al. | A systematic approach to novel virus discovery in emerging infectious disease outbreaks | |
| Sanada et al. | Transmission of HBV DNA mediated by ceramide-triggered extracellular vesicles | |
| Van Baalen et al. | Detection of nonhemagglutinating influenza a (h3) viruses by enzyme-linked immunosorbent assay in quantitative influenza virus culture | |
| Pacciarini et al. | Persistent replication of severe acute respiratory syndrome coronavirus in human tubular kidney cells selects for adaptive mutations in the membrane protein | |
| Lu et al. | Development and evaluation of one-step TaqMan real-time reverse transcription-PCR assays targeting nucleoprotein, matrix, and hemagglutinin genes of equine influenza virus | |
| Parvin et al. | Differential replication properties among H9N2 avian influenza viruses of Eurasian origin | |
| Zhang et al. | Persistent infection with a rabbit hepatitis E virus created by a reverse genetics system | |
| Rodriguez-Frandsen et al. | Viral determinants in H5N1 influenza A virus enable productive infection of HeLa cells | |
| Zhang et al. | Generation of a Bactrian camel hepatitis E virus by a reverse genetics system | |
| Liu | Molecular detection of human viral pathogens | |
| CA2937088C (en) | Method for generating high-titer hepatitis e virus stocks and titration assay for hepatitis e virus | |
| Lin et al. | Development of strand-specific real-time RT-PCR for the analysis of SCRV transcription and replication dynamics | |
| HK1230654A1 (en) | Method for generating high-titer hepatitis e virus stocks and titration assay for hepatitis e virus | |
| HK1230654B (en) | Method for generating high-titer hepatitis e virus stocks and titration assay for hepatitis e virus | |
| US20100255459A1 (en) | Control for virus detection assays based on reverse-transcription polymerase chain reaction | |
| Otsuki et al. | Elucidation of the full genetic information of Japanese rubella vaccines and the genetic changes associated with in vitro and in vivo vaccine virus phenotypes | |
| Yang et al. | Establishment and optimization of a rapid and convenient viral RNA transcript copy reduction neutralization test (VcRNT) for quantification of hantaan orthohantavirus (HTNV) neutralizing antibodies | |
| Lee et al. | M‐specific reverse transcription loop‐mediated isothermal amplification for detection of pandemic (H1N1) 2009 virus | |
| CN110846437A (zh) | 鸡细小病毒与h9亚型禽流感病毒二重pcr检测引物组、试剂盒及方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190225 |
|
| EEER | Examination request |
Effective date: 20190225 |
|
| EEER | Examination request |
Effective date: 20190225 |